Released: Wednesday 31st May 2023

 Press release here:

Merck Increases Global Commitment to Biosafety
Testing With € 35 Million Investment in Scotland
• Responds to global demand for biosafety testing for drug development
and commercialization
• Expansion creates nearly 500 new jobs in Glasgow and Stirling
• Company’s investment to boost global testing capacity now tops €350
million since mid-2022
Glasgow, Scotland, May 31, 2023 – Merck, a leading science and technology
company, invests € 35 million in biosafety testing at its Glasgow and Stirling sites,
Scotland. Biosafety testing is a critical step in the drug development and
manufacturing process that ensures drugs are safe, efficacious, and meet regulatory
requirements. The expansion will create nearly 500 new jobs, bringing Merck’s
workforce to over 1,200 employees across the two sites.
“We remain committed to ensuring the safety of the world's medicines through our
state-of-the-art testing solutions for our customers around the world that drive new
treatments,” said Dirk Lange, Head of Life Science Services, Merck Life Science.
“Since mid-2022, we have invested more than € 350 million in our global testing
network to meet the growing demand for these services.”
The centerpiece of the investment is a new, 1,200-square-meter facility in Glasgow,
which will house molecular biology and sequencing services. The company will
expand testing capacity in its current buildings with biosafety testing, analytical
development, and viral clearance suites. The latest investment follows the
News Release
Page 2 of 2
Classification: CONFIDENTIAL
company’s recent Rockville, Maryland, USA, and Shanghai, China testing
expansions.
“Merck has a wealth of testing expertise spanning over 75 years, including 33 years
here in Scotland,” said David McClelland, Site Head and Managing Director for the
Scottish sites. “The biosafety testing services at our sites in Glasgow and Stirling
have been experiencing strong, double-digit growth for several years. This
investment is a significant announcement for Merck in Scotland and an
acknowledgment of the great work of our on-site teams.”
With its BioReliance® testing services portfolio, Merck performs more than 20,000
studies in the UK annually for more than 500 clients globally.
BioReliance® Contract Testing Services and the recently formed Millipore® CTDMO
Services are part of the Life Science Services business unit, which together with
the Process Solutions business is one of Merck's “Big 3” growth drivers. By 2025,
these businesses are expected to generate approximately 80% of targeted sales
growth, and more than 50% of total sales in 2025. The company aims to increase
its Group sales to approximately €25 billion by 2025.
All Merck news releases are distributed by email at the same time they become available on the Merck
website. Please go to www.merckgroup.com/subscribe to register online, change your selection or
discontinue this service.

About Merck
Merck, a leading science and technology company, operates across life science, healthcare and
electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives
every day by creating more joyful and sustainable ways to live. From providing products and services
that accelerate drug development and manufacturing as well as discovering unique ways to treat the
most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022,
Merck generated sales of € 22.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and
scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains
the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and
brand. The only exceptions are the United States and Canada, where the business sectors of Merck
operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics